Bristol-Myers Squibb (NYSE:BMY) Hits New 1-Year Low at $41.04

Shares of Bristol-Myers Squibb (NYSE:BMYGet Free Report) hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $41.04 and last traded at $41.30, with a volume of 847028 shares. The stock had previously closed at $41.24.

Wall Street Analyst Weigh In

BMY has been the subject of a number of research analyst reports. Redburn Atlantic lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $77.00 to $54.00 in a research note on Tuesday, February 6th. StockNews.com raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 23rd. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. Finally, BMO Capital Markets reduced their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday, April 26th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $60.00.

Get Our Latest Report on BMY

Bristol-Myers Squibb Price Performance

The stock has a fifty day moving average price of $47.59 and a 200-day moving average price of $49.56. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99 and a current ratio of 1.11. The firm has a market capitalization of $82.97 billion, a PE ratio of -13.20, a P/E/G ratio of 13.96 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The firm had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. During the same period in the previous year, the business earned $2.05 EPS. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. Sell-side analysts forecast that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, May 1st. Investors of record on Friday, April 5th were paid a dividend of $0.60 per share. The ex-dividend date was Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 5.86%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Milestone Investment Advisors LLC acquired a new stake in Bristol-Myers Squibb during the 3rd quarter worth about $27,000. ESL Trust Services LLC acquired a new stake in Bristol-Myers Squibb during the 1st quarter worth about $27,000. Northwest Financial Advisors acquired a new stake in Bristol-Myers Squibb during the 4th quarter worth about $27,000. Accordant Advisory Group Inc acquired a new stake in Bristol-Myers Squibb during the 1st quarter worth about $31,000. Finally, Pacific Capital Wealth Advisors Inc. acquired a new stake in Bristol-Myers Squibb during the 4th quarter worth about $34,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

About Bristol-Myers Squibb

(Get Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

See Also

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.